# Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.

> **NCT05190094** · PHASE2 · RECRUITING · sponsor: **International Cancer Research Group, United Arab Emirates** · enrollment: 80 (estimated)

## Conditions studied

- Hormonal Receptors Positive, HER2 Negative, Advanced Breast Cancer

## Interventions

- **DRUG:** Combination of Palbociclib and aromatase inhibitor (Letrozole or Anastrozole)

## Key facts

- **NCT ID:** NCT05190094
- **Lead sponsor:** International Cancer Research Group, United Arab Emirates
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-20
- **Primary completion:** 2025-12
- **Final completion:** 2026-06
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2025-05-07

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05190094

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05190094, "Prediction of Treatment Efficacy of the Combination of Palbociclib/(Letrozole or Anastrozole) in First Line Metastatic Women With Luminal, HER2 Negative Advanced Breast Cancer, Using Infrared Laser Spectroscopy Analysis on Liquid Biopsies.". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05190094. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*